RLMD — Breakout After 10-Month ConsolidationRLMD has finally broken out above its long-standing resistance after nearly 10 months of consolidation. The breakout is supported by good volume, which adds strength and reliability to the move.
🔑 Why This is Significant
Long consolidation: When a stock trades sideways for months, it builds strong
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.879 EUR
−77.26 M EUR
0.00 EUR
26.44 M
About Relmada Therapeutics, Inc.
Sector
Industry
CEO
Sergio Traversa
Website
Headquarters
Coral Gables
Founded
2012
ISIN
US75955J4022
FIGI
BBG01B2GYQT0
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange Relmada Therapeutics Inc stocks are traded under the ticker 4E2.
We've gathered analysts' opinions on Relmada Therapeutics Inc future price: according to them, 4E2 price has a max estimate of 0.92 EUR and a min estimate of 0.92 EUR. Watch 4E2 chart and read a more detailed Relmada Therapeutics Inc stock forecast: see what analysts think of Relmada Therapeutics Inc and suggest that you do with its stocks.
Yes, you can track Relmada Therapeutics Inc financials in yearly and quarterly reports right on TradingView.
Relmada Therapeutics Inc is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
4E2 earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.39 EUR resulting in a 34.78% surprise. The estimated earnings for the next quarter are −0.38 EUR per share. See more details about Relmada Therapeutics Inc earnings.
Relmada Therapeutics Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
4E2 net income for the last quarter is −8.38 M EUR, while the quarter before that showed −16.23 M EUR of net income which accounts for 48.40% change. Track more Relmada Therapeutics Inc financial stats to get the full picture.
No, 4E2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 17 employees. See our rating of the largest employees — is Relmada Therapeutics Inc on this list?
Like other stocks, 4E2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Relmada Therapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.